According to KC in the last call "With respect to the publication, there is still some chance that there could be a publication in December. However, we think that it's more likely to be in the early part of Q1."
That's the latest I've heard.
living - unfortunately yes! I don't think FDA will reverse decision but I still think it is clearly best in class for high trigs which is a billion $ market and "eventually" docs and new management? will help realize it's value. I think it will be dead money for a while though.
I see you point Donormaster about demand but respectfully disagree that increased population growth "essentially means nothing to SVA". Since Hep B occurs significantly through vertical (maternal-fetal) transmission the vaccine is given at birth. Hep A also has high transmission rates in the young and vaccination begins at 2 months of age. Certainly increasing demand is important but even the same demand in a larger population will mean more vaccines sold. Also folks having more kids are likely to be more affluent in the urban areas and will want to and can afford to vaccinate their kids. I guess we'll see who's right in a few years :) Good luck to us all.
No more 1 baby policy in China
Long time SVA shareholder, don't post much but surprised no one picked up on this. This could be HUGE for SVA!
Who gets the vast majority of Imunizations - particularly Hep A and B? -------BABIES!
Granted it won't happen for at least 9 months but we should see a significant impact in 1-2 years for those long term holders.
Agree Earwax - It will be NEJM. If you recall the original Exact study in 2004 was puplished in the NEJM (Fecal DNA versus Fecal Occult Blood for Colorectal-Cancer Screening in an Average-Risk Population) and this present study is certainly of greater medical significance.